Literature DB >> 2044330

An updated comparison of drug dosing methods. Part IV: Vancomycin.

R D Pryka1, K A Rodvold, S M Erdman.   

Abstract

The resurgence of the use of and interest in vancomycin, in conjunction with the high degree of interpatient variability in its pharmacokinetic profile, has prompted the development of many and varied dosing methods. Several dosing nomograms have been proposed and evaluated, methods which are useful for initial dosing but do not allow for individualisation of dosage. Given these constraints, several investigators have attempted to apply conventional least-squares regression techniques and, more recently, Bayesian methodologies using either 1- or 2-compartment pharmacokinetic models. Comparative information evaluating algorithmic methods demonstrates that those of Moellering and Lake offer the least biased and most precise predictions of vancomycin dosage. Patient individualisation using conventional least-squares methodology offers some improvement over nomogram-based methods, both in predictive performance and in dosage adjustment once serum concentration data are available. Overall, the latest data indicate that regimens which incorporate Bayesian principles tend to give better results than nomogram-based or conventional least-squares dosing methods for this drug. Despite the advances in methods for dosing vancomycin, several questions remain to be answered. A lack of convincing evidence of a correlation between serum concentrations and therapeutic outcome has prompted debate over the need for serum concentration monitoring and, if it is needed, over which patient population would most benefit. Secondly, little comparative information is currently available as to the dosing of vancomycin in paediatric and neonatal patient populations. Several nomograms for initial dosing have been proposed, but only 2 have been subject to subsequent testing. Finally, information regarding cost-effectiveness and the quality of patient outcome is lacking from the current literature.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2044330     DOI: 10.2165/00003088-199120060-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  59 in total

1.  Vancomycin: report on treatment of patients with severe staphylococcal infections.

Authors:  A A DUTTON; P C ELMES
Journal:  Br Med J       Date:  1959-05-02

2.  Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations.

Authors:  K A Rodvold; R D Pryka; M Garrison; J C Rotschafer
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

3.  Evaluation of a method for initiating vancomycin therapy: experience in 205 patients.

Authors:  K D Lake; C D Peterson
Journal:  Pharmacotherapy       Date:  1988       Impact factor: 4.705

4.  Routine monitoring of serum vancomycin concentrations: waiting for proof of its value.

Authors:  D J Edwards; S Pancorbo
Journal:  Clin Pharm       Date:  1987-08

5.  Application of a Bayesian method to monitor and adjust vancomycin dosage regimens.

Authors:  A K Hurst; M A Yoshinaga; G H Mitani; K A Foo; R W Jelliffe; E C Harrison
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center.

Authors:  D P Levine; R D Cushing; J Jui; W J Brown
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

7.  The clinical pharmacology of vancomycin in seriously ill preterm infants.

Authors:  M D Reed; R M Kliegman; J S Weiner; M Huang; T S Yamashita; J L Blumer
Journal:  Pediatr Res       Date:  1987-09       Impact factor: 3.756

8.  Evaluation of the vancomycin-clearance:creatinine-clearance relationship for predicting vancomycin dosage.

Authors:  G R Matzke; J M Kovarik; M J Rybak; S C Boike
Journal:  Clin Pharm       Date:  1985 May-Jun

9.  Vancomycin pharmacokinetics in small, seriously ill infants.

Authors:  S H Naqvi; W J Keenan; R M Reichley; K P Fortune
Journal:  Am J Dis Child       Date:  1986-02

Review 10.  Vancomycin pharmacokinetics in very low birth weight neonates.

Authors:  M B Leonard; G Koren; D K Stevenson; C G Prober
Journal:  Pediatr Infect Dis J       Date:  1989-05       Impact factor: 2.129

View more
  14 in total

Review 1.  Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children.

Authors:  K A Rodvold; J A Everett; R D Pryka; D M Kraus
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

3.  Vancomycin Serum Concentration Monitoring : The Middle Ground is Best.

Authors:  F Marra; B Cairns; P Jewesson
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

4.  Initial dose of vancomycin based on body weight and creatinine clearance to minimize inadequate trough levels in Japanese adults.

Authors:  N Maki; A Ohkuchi; Y Tashiro; M R Kim; M Le; T Sakamoto; S Matsubara; Y Hakamata
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-06       Impact factor: 3.267

Review 5.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 6.  Methods for clinical monitoring of cyclosporin in transplant patients.

Authors:  R J Dumont; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

Review 7.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 8.  Glycopeptides and nephrotoxicity.

Authors:  A W Chow; R M Azar
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

9.  Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.

Authors:  K Vance-Bryan; D R Guay; S S Gilliland; K A Rodvold; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

Review 10.  Vancomycin: pharmacokinetics and administration regimens in neonates.

Authors:  Matthijs de Hoog; Johan W Mouton; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.